About idorsia ltd. - IDRSF
Idorsia Ltd. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of medicines for medical needs. It operates through the following geographical segments: Switzerland, United States, Japan, and EUCAN. The company was founded on March 3, 2017 and is headquartered in Allschwil, Switzerland.
IDRSF At a Glance
Idorsia Ltd.
Hegenheimermattweg 91
Allschwil, Basel-Landschaft (Basle Country) 4123
| Phone | 41-58-844-10-10 | Revenue | 127.75M | |
| Industry | Pharmaceuticals: Major | Net Income | -299,496,665.61 | |
| Sector | Health Technology | Employees | N/A | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
IDRSF Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 1.295 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -3.827 |
| Enterprise Value to Sales | 11.075 |
| Total Debt to Enterprise Value | 0.98 |
IDRSF Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | N/A |
| Receivables Turnover | 3.099 |
| Total Asset Turnover | 0.222 |
IDRSF Liquidity
| Current Ratio | 0.576 |
| Quick Ratio | 0.435 |
| Cash Ratio | 0.281 |
IDRSF Profitability
| Gross Margin | 52.187 |
| Operating Margin | -305.302 |
| Pretax Margin | -234.048 |
| Net Margin | -234.434 |
| Return on Assets | -51.983 |
| Return on Equity | N/A |
| Return on Total Capital | -609.848 |
| Return on Invested Capital | N/A |
IDRSF Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | 2,823.554 |
| Total Debt to Total Assets | 248.402 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 2,354.885 |